OOIR: Observatory of International Research

Papers

(The median citation count of Alzheimers & Dementia is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
2020 Alzheimer's disease facts and figures	1644
2021 Alzheimer's disease facts and figures	1512
2022 Alzheimer's disease facts and figures	1056
2023 Alzheimer's disease facts and figures	450
Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020–2060)	356
Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019	315
World‐Wide FINGERS Network: A global approach to risk reduction and prevention of dementia	248
In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET	165
The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease	164
Hypothesis: Tau pathology is an initiating factor in sporadic Alzheimer's disease	163
COVID‐19 and dementia: Analyses of risk, disparity, and outcomes from electronic health records in the US	156
The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease	153
Plasma p‐tau181, p‐tau217, and other blood‐based Alzheimer's disease biomarkers in a multi‐ethnic, community study	151
Global estimates on the number of persons across the Alzheimer's disease continuum	139
The chronic neuropsychiatric sequelae of COVID‐19: The need for a prospective study of viral impact on brain functioning	132
Changes in cognitive functioning after COVID‐19: A systematic review and meta‐analysis	120
Tackling challenges in care of Alzheimer's disease and other dementias amid the COVID‐19 pandemic, now and in the future	115
Blood neuro‐exosomal synaptic proteins predict Alzheimer's disease at the asymptomatic stage	115
Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum	111
Visualization of neurofibrillary tangle maturity in Alzheimer's disease: A clinicopathologic perspective for biomarker research	108
Proteomic and biological profiling of extracellular vesicles from Alzheimer's disease human brain tissues	103
Vascular contributions to cognitive impairment and dementia (VCID): A report from the 2018 National Heart, Lung, and Blood Institute and National Institute of Neurological Disorders and Stroke Worksho	102
Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia	102
Alzheimer's‐like signaling in brains of COVID‐19 patients	100
GABAergic dysfunction in excitatory and inhibitory (E/I) imbalance drives the pathogenesis of Alzheimer's disease	94

Cognitive impairment in sporadic cerebral small vessel disease: A systematic review and meta‐analysis	91
A ketogenic drink improves cognition in mild cognitive impairment: Results of a 6‐month RCT	88
Retinal imaging in Alzheimer's and neurodegenerative diseases	86
Acute systemic inflammation exacerbates neuroinflammation in Alzheimer's disease: IL‐1β drives amplified responses in primed astrocytes and neuronal network dysfunction	85
The Brain Chart of Aging: Machine‐learning analytics reveals links between brain aging, white matter disease, amyloid burden, and cognition in the iSTAGING consortium of 10,216 harmonized MR scans	85
Comparison of serum neurodegenerative biomarkers among hospitalized COVID‐19 patients versus non‐COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer's dementia	83
Prevalence of cerebral amyloid angiopathy: A systematic review and meta‐analysis	83
World Alzheimer Report 2019: Attitudes to dementia, a global survey	82
Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities	81
Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease	79
Characterization of pre‐analytical sample handling effects on a panel of Alzheimer's disease–related blood‐based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) wor	79
Midlife vascular risk factors and risk of incident dementia: Longitudinal cohort and Mendelian randomization analyses in the UK Biobank	78
Gait variability across neurodegenerative and cognitive disorders: Results from the Canadian Consortium of Neurodegeneration in Aging (CCNA) and the Gait and Brain Study	77
A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study	76
Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosis	74
The role of mitochondrial dysfunction in Alzheimer's disease pathogenesis	73
An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum	73
36‐month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease	70
Regional brain iron associated with deterioration in Alzheimer's disease: A large cohort study and theoretical significance	69
Neurovascular and immune mechanisms that regulate postoperative delirium superimposed on dementia	69
Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p‐tau	68
Diagnostic criteria for apathy in neurocognitive disorders	68
Dementia is an age‐independent risk factor for severity and death in COVID‐19 inpatients	64
The impact of diabetes on cognitive impairment and its progression to dementia	64
The estimation of the global prevalence of dementia from 1990‐2019 and forecasted prevalence through 2050: An analysis for the Global Burden of Disease (GBD) study 2019	64
Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel	63
Multimorbidity burden and dementia risk in older adults: The role of inflammation and genetics	63
Dementia in Latin America: Paving the way toward a regional action plan	61
Large‐scale plasma proteomic profiling identifies a high‐performance biomarker panel for Alzheimer's disease screening and staging	59
Black and White individuals differ in dementia prevalence, risk factors, and symptomatic presentation	56
Associations of loneliness with risk of Alzheimer's disease dementia in the Framingham Heart Study	55
White matter hyperintensity topography in Alzheimer's disease and links to cognition	54
Integrative metabolomics‐genomics approach reveals key metabolic pathways and regulators of Alzheimer's disease	54
Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease	53
Age‐related calcium dysregulation linked with tau pathology and impaired cognition in non‐human primates	53
Repetitive negative thinking is associated with amyloid, tau, and cognitive decline	52
ENGAGE and EMERGE: Truth and consequences?	52
Synaptic density and cognitive performance in Alzheimer's disease: A PET imaging study with [¹¹C]UCB‐J	52
Toward a theory‐based specification of non‐pharmacological treatments in aging and dementia: Focused reviews and methodological recommendations	52
Education differentially contributes to cognitive reserve across racial/ethnic groups	51
Extracellular vesicle biomarkers of Alzheimer's disease associated with sub‐clinical cognitive decline in late middle age	50
Relationships between memory decline and the use of metformin or DPP4 inhibitors in people with type 2 diabetes with normal cognition or Alzheimer's disease, and the role APOE carrier status	50
Further understanding the connection between Alzheimer's disease and Down syndrome	49
The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau	49
Sleep characteristics and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact older adults: The CABLE study	47
Emerge and Engage topline results: Phase 3 studies of aducanumab in early Alzheimer’s disease	47
Whole‐genome sequencing reveals new Alzheimer's disease–associated rare variants in loci related to synaptic function and neuronal development	46
Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease	46
Role of chronic neuroinflammation in neuroplasticity and cognitive function: A hypothesis	46
Traditional Chinese medicine for dementia	45

Plasma hydrogen sulfide: A biomarker of Alzheimer's disease and related dementias	44
An accurate fully automated panel of plasma biomarkers for Alzheimer's disease	43
A novel sensitive assay for detection of a biomarker of pericyte injury in cerebrospinal fluid	43
Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort	42
Diversity of transcriptomic microglial phenotypes in aging and Alzheimer's disease	42
Plasma and CSF biomarkers in a memory clinic: Head‐to‐head comparison of phosphorylated tau immunoassays	41
First amyloid β1‐42 certified reference material for re‐calibrating commercial immunoassays	41
Plasma Aβ42/40 ratio, p‐tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross‐sectional and longitudinal study in the AIBL cohort	40
Contribution of mixed pathology to medial temporal lobe atrophy in Alzheimer's disease	40
Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification	40
MarkVCID cerebral small vessel consortium: II. Neuroimaging protocols	40
Stroke and dementia, leading causes of neurological disability and death, potential for prevention	39
MRI‐assessed locus coeruleus integrity is heritable and associated with multiple cognitive domains, mild cognitive impairment, and daytime dysfunction	39
Current directions in tau research: Highlights from Tau 2020	38
A novel tau‐based rhesus monkey model of Alzheimer's pathogenesis	38
Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance	38
Concomitant neurodegenerative pathologies contribute to the transition from mild cognitive impairment to dementia	38
Validity of the 2014 traumatic encephalopathy syndrome criteria for CTE pathology	37
Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease‐modifying therapies	37
MarkVCID cerebral small vessel consortium: I. Enrollment, clinical, fluid protocols	37
Plasma P‐tau181 to Aβ42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease	36
Characterizing plasma NfL in a community‐dwelling multi‐ethnic cohort: Results from the HABLE study	36
APOE interacts with tau PET to influence memory independently of amyloid PET in older adults without dementia	36
Plasma IL‐12/IFN‐γ axis predicts cognitive trajectories in cognitively unimpaired older adults	36
Bayes analysis supports null hypothesis of anti‐amyloid beta therapy in Alzheimer's disease	36
ABCA7 and the altered lipidostasis hypothesis of Alzheimer's disease	35
Small vessel disease more than Alzheimer's disease determines diffusion MRI alterations in memory clinic patients	35
The costs of developing treatments for Alzheimer's disease: A retrospective exploration	35
The worldwide costs of dementia in 2019	35
Dietary fatty acids and risk of Alzheimer's disease and related dementias: Observations from the Washington Heights‐Hamilton Heights‐Inwood Columbia Aging Project (WHICAP)	34
Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia	33
The Longitudinal Early‐onset Alzheimer's Disease Study (LEADS): Framework and methodology	33
Alzheimer's disease alters oligodendrocytic glycolytic and ketolytic gene expression	33
Long‐term community noise exposure in relation to dementia, cognition, and cognitive decline in older adults	33
The economic cost of delirium: A systematic review and quality assessment	33
Mediterranean and Western diet effects on Alzheimer's disease biomarkers, cerebral perfusion, and cognition in mid‐life: A randomized trial	33
Diversity in Alzheimer's disease drug trials: The importance of eligibility criteria	33
Head injury and 25‐year risk of dementia	32
Dementia in Africa: Current evidence, knowledge gaps, and future directions	32
Proton pump inhibitors act with unprecedented potencies as inhibitors of the acetylcholine biosynthesizing enzyme—A plausible missing link for their association with incidence of dementia	32
A roadmap to advance delirium research: Recommendations from the NIDUS Scientific Think Tank	32
Daytime napping and Alzheimer's dementia: A potential bidirectional relationship	32
APOE and dementia – resequencing and genotyping in 105,597 individuals	32
Consideration of sex and gender in Alzheimer's disease and related disorders from a global perspective	32
Distinct effects of beta‐amyloid and tau on cortical thickness in cognitively healthy older adults	32
Increased APOE ε4 expression is associated with the difference in Alzheimer's disease risk from diverse ancestral backgrounds	32
Reproductive period and dementia: A 44‐year longitudinal population study of Swedish women	31
Impact of COVID‐19 on the Onset and Progression of Alzheimer's Disease and Related Dementias: A Roadmap for Future Research	31
Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve	31
Potential role of chitinase‐3‐like protein 1 (CHI3L1/YKL‐40) in neurodegeneration and Alzheimer's disease	31
Tau and apolipoprotein E modulate cerebrovascular tight junction integrity independent of cerebral amyloid angiopathy in Alzheimer's disease	31
Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease	31
Age‐dependent amyloid deposition is associated with white matter alterations in cognitively normal adults during the adult life span	31
Association of lifespan cognitive reserve indicator with the risk of mild cognitive impairment and its progression to dementia	30
State‐of‐the‐art of lumbar puncture and its place in the journey of patients with Alzheimer's disease	30
The AHEAD 3‐45 Study: Design of a prevention trial for Alzheimer's disease	30
Water exchange rate across the blood‐brain barrier is associated with CSF amyloid‐β 42 in healthy older adults	30
Actigraphy‐estimated sleep and 24‐hour activity rhythms and the risk of dementia	30
The APOE ε4 exerts differential effects on familial and other subtypes of Alzheimer's disease	29
Salivary lactoferrin as biomarker for Alzheimer's disease: Brain‐immunity interactions	29
International drive to illuminate delirium: A developing public health blueprint for action	29
Speech‐in‐noise hearing impairment is associated with an increased risk of incident dementia in 82,039 UK Biobank participants	29
Suicide risk in first year after dementia diagnosis in older adults	29
Alzheimer's disease biomarkers in Black and non‐Hispanic White cohorts: A contextualized review of the evidence	28
Genome‐wide association study of rate of cognitive decline in Alzheimer's disease patients identifies novel genes and pathways	28
Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes	28
Refined carbohydrate‐rich diet is associated with long‐term risk of dementia and Alzheimer's disease in apolipoprotein E ε4 allele carriers	28
Sequences of cognitive decline in typical Alzheimer's disease and posterior cortical atrophy estimated using a novel event‐based model of disease progression	28
Mitophagy alterations in Alzheimer's disease are associated with granulovacuolar degeneration and early tau pathology	28
APOE alleles’ association with cognitive function differs across Hispanic/Latino groups and genetic ancestry in the study of Latinos‐investigation of neurocognitive aging (HCHS/SOL)	28
Metabolomics and incident dementia in older Chinese adults: The Shanghai Aging Study	28
Association of diabetes with stroke and post‐stroke dementia: A population‐based cohort study	27
Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study	27
The biogenesis and biology of amyloid β oligomers in the brain	27
Rural‐urban differences in diagnostic incidence and prevalence of Alzheimer's disease and related dementias	27
Functional insights from biophysical study of TREM2 interactions with apoE and Aβ_1‐42	27
A critical appraisal of tau‐targeting therapies for primary and secondary tauopathies	27
Reactive or transgenic increase in microglial TYROBP reveals a TREM2‐independent TYROBP–APOE link in wild‐type and Alzheimer's‐related mice	27
Medical comorbidities and ethnicity impact plasma Alzheimer's disease biomarkers: Important considerations for clinical trials and practice	26
Brain health: Key to health, productivity, and well‐being	26

Mild behavioral impairment is associated with progression to Alzheimer's disease: A clinicopathological study	26
Association of plasma biomarkers, p‐tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long‐term clinical Alzheimer's disease risk: Results from a prospective coho	26
C‐reactive protein levels and risk of dementia—Observational and genetic studies of 111,242 individuals from the general population	26
Tracing temporal trends in dementia incidence over 25 years in central Stockholm, Sweden	26
Sex differences in dementia and response to a lifestyle intervention: Evidence from Nordic population‐based studies and a prevention trial	26
Mild cognitive impairment among rural‐dwelling older adults in China: A community‐based study	26
Early prevention of cognitive impairment in the community population: The Beijing Aging Brain Rejuvenation Initiative	26
Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community‐engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4	25
ATN incorporating cerebrospinal fluid neurofilament light chain detects frontotemporal lobar degeneration	25
Effects of cocoa extract and a multivitamin on cognitive function: A randomized clinical trial	25
Epidemiology of early onset dementia and its clinical presentations in the province of Modena, Italy	25
Effect of periodontal treatment on preclinical Alzheimer's disease—Results of a trial emulation approach	25
Decoding perineuronal net glycan sulfation patterns in the Alzheimer's disease brain	25
Mitochondrial ROS control neuronal excitability and cell fate in frontotemporal dementia	25
Exploratory analysis of mtDNA haplogroups in two Alzheimer's longitudinal cohorts	25
Adherence to a Mediterranean diet and cognitive function in the Age‐Related Eye Disease Studies 1 & 2	25
Aducanumab: Appropriate use recommendations	25
Integrative functional genomic analysis of intron retention in human and mouse brain with Alzheimer's disease	24
Unhealthy foods may attenuate the beneficial relation of a Mediterranean diet to cognitive decline	24
COVID‐19 breakthrough infections and hospitalizations among vaccinated patients with dementia in the United States between December 2020 and August 2021	24
Differences between blood and cerebrospinal fluid glial fibrillary Acidic protein levels: The effect of sample stability	24
	24
Expectations and clinical meaningfulness of randomized controlled trials	24
Prevalence of dementia in India: National and state estimates from a nationwide study	24
Blood polyunsaturated omega‐3 fatty acids, brain atrophy, cognitive decline, and dementia risk	24
Targeting increased levels of APP in Down syndrome: Posiphen‐mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model	24
A prognostic model for overall survival in sporadic Creutzfeldt‐Jakob disease	23
Microglial INPP5D limits plaque formation and glial reactivity in the PSAPP mouse model of Alzheimer's disease	23
In situ spatial glycomic imaging of mouse and human Alzheimer's disease brains	23
Shift work and incidence of dementia: A Danish Nurse Cohort study	23
Genome‐wide transcriptome analysis identifies novel dysregulated genes implicated in Alzheimer's pathology	23
Cancer and risk of Alzheimer's disease: Small association in a nationwide cohort study	23
The BIN1 rs744373 Alzheimer's disease risk SNP is associated with faster Aβ‐associated tau accumulation and cognitive decline	23
Age‐stratified longitudinal study of Alzheimer's and vascular dementia patients	23
Detection of Alzheimer's disease amyloid beta 1‐42, p‐tau, and t‐tau assays	23
Biphasic cortical macro‐ and microstructural changes in autosomal dominant Alzheimer's disease	23
Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease	23
Late‐life physical activity relates to brain tissue synaptic integrity markers in older adults	22
TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels	22
How can population‐based studies best be utilized to reduce the global impact of dementia? Recommendations for researchers, funders, and policymakers	22
Perspective on the “African American participation in Alzheimer disease research: Effective strategies” workshop, 2018	22
Biofluid‐based biomarkers for Alzheimer's disease–related pathologies: An update and synthesis of the literature	22
Increased β‐site APP cleaving enzyme 1‐mediated insulin receptor cleavage in type 2 diabetes mellitus with cognitive impairment	22
Association of cardiovascular risk burden with risk of dementia and brain pathologies: A population‐based cohort study	22
CSF biomarkers and plasma p‐tau181 as predictors of longitudinal tau accumulation: Implications for clinical trial design	22
Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers	22
Hypothesis: JNK signaling is a therapeutic target of neurodegenerative diseases	22
Plasma proteins, cognitive decline, and 20‐year risk of dementia in the Whitehall II and Atherosclerosis Risk in Communities studies	22
Early dementia diagnosis, MCI‐to‐dementia risk prediction, and the role of machine learning methods for feature extraction from integrated biomarkers, in particular for EEG signal analysis	22
Open Peer Commentary to “Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019”	22
Association of traumatic brain injury with dementia and memory decline in older adults in the United States	21
Association of Life's Simple 7 with incident dementia and its modification by the apolipoprotein E genotype	21
Difficulty and help with activities of daily living among older adults living alone with cognitive impairment	21
Amyloid‐beta misfolding and GFAP predict risk of clinical Alzheimer's disease diagnosis within 17 years	21
Brain structures and networks responsible for stimulation‐induced memory flashbacks during forniceal deep brain stimulation for Alzheimer's disease	21
Tau pathologies mediate the association of blood pressure with cognitive impairment in adults without dementia: The CABLE study	21
Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings	21
The effect of adherence on cognition in a multidomain lifestyle intervention (FINGER)	21
Quantifying dementia prevention potential in the FINGER randomized controlled trial using the LIBRA prevention index	21
Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease	21
Test‐retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models	21
Characteristics of subjective cognitive decline associated with amyloid positivity	21
Slowing gait speed precedes cognitive decline by several years	21
Self‐reported obstructive sleep apnea, amyloid and tau burden, and Alzheimer's disease time‐dependent progression	21
Blood extracellular vesicles carrying synaptic function‐ and brain‐related proteins as potential biomarkers for Alzheimer's disease	21
Systematic in silico analysis of clinically tested drugs for reducing amyloid‐beta plaque accumulation in Alzheimer's disease	21
Comparative analytical performance of multiple plasma Aβ42 and Aβ40 assays and their ability to predict positron emission tomography amyloid positivity	21
Can active life mitigate the impact of diabetes on dementia and brain aging?	20
Association of life‐course depression with the risk of dementia in late life: A nationwide twin study	20
Elevated plasma neurofilament light predicts a faster rate of cognitive decline over 5 years in participants with objectively‐defined subtle cognitive decline and MCI	20
Neurodegeneration and astrogliosis in the entorhinal cortex in Alzheimer's disease: Stereological layer‐specific assessment and proteomic analysis	20
Lifestyle, multi‐omics features, and preclinical dementia among Chinese: The Taizhou Imaging Study	20
Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview	20
Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe	20
Quantifying progression in primary progressive aphasia with structural neuroimaging	20
Tau phosphorylation sites serine202 and serine396 are differently altered in chronic traumatic encephalopathy and Alzheimer's disease	20
Identification of the Aβ37/42 peptide ratio in CSF as an improved Aβ biomarker for Alzheimer's disease	20
AD risk score for the early phases of disease based on unsupervised machine learning	19
A combination model of AD biomarkers revealed by machine learning precisely predicts Alzheimer's dementia: China Aging and Neurodegenerative Initiative (CANDI) study	19
Cardiometabolic multimorbidity accelerates cognitive decline and dementia progression	19
Plasma amyloid β levels are driven by genetic variants near APOE, BACE1, APP, PSEN2: A genome‐wide association study in over 12,000 non‐demented participants	19
Plasma amyloid beta predicts conversion to dementia in subjects with mild cognitive impairment: The BALTAZAR study	19
APP accumulates with presynaptic proteins around amyloid plaques: A role for presynaptic mechanisms in Alzheimer's disease?	19
APOE genotype, hippocampus, and cognitive markers of Alzheimer's disease in American Indians: Data from the Strong Heart Study	19
White matter hyperintensities and longitudinal cognitive decline in cognitively normal populations and across diagnostic categories: A meta‐analysis, systematic review, and recommendations for future	19
Genome‐wide association and multi‐omics studies identify MGMT as a novel risk gene for Alzheimer's disease among women	19
Generalizability of findings from a clinical sample to a community‐based sample: A comparison of ADNI and ARIC	19
Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline	19
MAPT haplotype–stratified GWAS reveals differential association for AD risk variants	19
Ophthalmic conditions associated with dementia risk: The Cardiovascular Health Study	19
Cerebral small vessel disease burden and cognitive and functional outcomes after stroke: A multicenter prospective cohort study	19
Clinical performance and robustness evaluation of plasma amyloid‐β_42/40 prescreening	19
Characterization of dementia with Lewy bodies (DLB) and mild cognitive impairment using the Lewy body dementia module (LBD‐MOD)	18
Longitudinal association of apolipoprotein E and sleep with incident dementia	18
Pathogenesis of sporadic Alzheimer's disease by deficiency of NMDA receptor subunit GluN3A	18